A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, intramuscular injection, antipsychotic agents, risperidone, long-acting injectable
Eligibility Criteria
Inclusion Criteria: Diagnosis of schizophrenia by the criteria of Diagnostic and Statistical Manual of Mental Diseases, 4th Edition (DSM-IV ) treatment with an antipsychotic drug (up to 6 milligrams/day of risperidone or equivalent dose) for 28 days before study initiation with no change in the dosage Total Positive and Negative Syndrome Scale (PANSS) score >=60 and <120 at start of study. Exclusion Criteria: Diagnosis of mental disease other than schizophrenia treated with a sustained-release injection of other antipsychotic medications within 60 days before the initiation of the study history of cerebrovascular accident, convulsive disorder such as epilepsy, diabetes mellitus, liver disease, kidney disease, cardiovascular disorder, malignancy or physical exhaustion due to dehydration or malnutrition have risk factors of diabetes mellitus, such as hyperglycemia.